Abstract

Both aging and diabetes are characterized by the formation of advanced glycation end products (AGEs). Both exhibit other similarities including deficits in wound healing that are associated with higher rates of fibroblast apoptosis. In order to investigate a potential mechanism for enhanced fibroblast apoptosis in diabetes and aged individuals, experiments were carried out to determine whether the predominant advanced glycation end product in skin, N-epsilon-(carboxymethyl) lysine (CML)-collagen, could induce fibroblast apoptosis. In vivo experiments established that CML-collagen but not unmodified collagen induced fibroblast apoptosis and that apoptosis was dependent upon caspase-3, -8, and -9 activity. In vitro experiments demonstrated that CML-collagen but not control collagen induced a time- and dose-dependent increase in fibroblast apoptosis. By use of blocking antibodies, apoptosis was shown to be mediated through receptor for AGE signaling. AGE-induced apoptosis was largely dependent on the effector caspase, caspase-3, which was activated through both cytoplasmic (caspase-8-dependent) and mitochondrial (caspase-9) pathways. CML-collagen had a global effect of enhancing mRNA levels of pro-apoptotic genes that included several classes of molecules including ligands, receptors, adaptor molecules, mitochondrial proteins, and others. However, the pattern of expression was not identical to the pattern of apoptotic genes induced by tumor necrosis factor alpha.

Highlights

  • Advanced glycation end products (AGEs)1 result from nonenzymatic reactions of carbohydrates and oxidized lipids with proteins [1, 2]

  • In order to investigate a potential mechanism for enhanced fibroblast apoptosis in diabetes and aged individuals, experiments were carried out to determine whether the predominant advanced glycation end product in skin, N-⑀-(carboxymethyl) lysine (CML)-collagen, could induce fibroblast apoptosis

  • In Vivo Induction of Apoptosis by CML-collagen—To study the effect of advanced glycation end products (AGEs) on fibroblast apoptosis in vivo, 100 ␮g of CML-collagen or control collagen was injected in the scalp of CD1 mice

Read more

Summary

Introduction

Advanced glycation end products (AGEs) result from nonenzymatic reactions of carbohydrates and oxidized lipids with proteins [1, 2]. Ture isomerizes to a more reactive ketoamine (Amadori product), which may undergo additional rearrangement, dehydration, condensation, and oxidation reactions These structures can result in protein cross-links and in a variety of protein modifications that collectively are known as advanced glycation end products [3]. By functionally blocking AGE activity or by applying AGEs in vivo, it has been shown that AGEs contribute to several pathologic processes These include diabetes-associated cataract formation, nephropathy, retinopathy, neuropathy, and periodontal disease [15,16,17,18,19,20]. Other receptors/binding proteins include macrophage scavenger receptor types I and II, oligosaccharyl transferase-48 (AGE-R1), 80K-H phosphoprotein (AGE-R2), and galectin-3 (AGE-R3). AGEs can modulate inflammatory events by stimulating production of reactive oxygen species, chemotaxis, activation of monocytes/ macrophages, and stimulation of interleukin-1 and TNF production [25,26,27,28,29,30]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call